MedTrace Logo

Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines

NCT06314724 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 642

Last updated 2025-01-27

No results posted yet for this study

Summary

This is a Phase Ⅲ, randomized, double-blind, active-controlled study to assess the immunogenicity and safety of the varicella vaccine,Live (hereinafter referred to as "varicella vaccine")manufactured by Sinovac (Dalian) Vaccine Technology Co., LTD.(hereinafter referred to as "Sinovac").

Conditions

  • Varicella

Interventions

BIOLOGICAL

Varicella Vaccine

lyophilized powder,subcutaneous injection

BIOLOGICAL

Varivax

lyophilized powder,subcutaneous injection

Sponsors & Collaborators

  • Sinovac (Dalian) Vaccine Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Rommel Crisenio M. Lobo, MD · Cardinal Santos Medical Center

  • Nancy Nazaire Bermal, MD · San Juan de Dios Educational Foundation, lnc.-Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Months
Max Age
15 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-29
Primary Completion
2024-09-06
Completion
2024-09-06

Countries

  • Philippines

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06314724 on ClinicalTrials.gov